Across 100 patients in three Phase III studies, Vertex's Casgevy showed lasting benefits for more than five years.

Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab with chemotherapy, achieved ...

BioAtla has presented first-in-human Phase I study data of its anticancer therapy, BA3182, targeting those with metastatic adenocarcinoma.

Biogen has commenced dosing in the Phase III PROMINENT trial, assessing the efficacy and safety of the felzartamab drug.

Tango has dosed the first subject in the Phase I/II trial of TNG462 with Revolution Medicines' daraxonrasib or zoldonrasib.

INmune Bio said that a subset of Alzheimer's disease patients in the study showed clinical benefit from the therapy.

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

Pfizer's recent trial termination makes it yet another company facing challenges with CD47 studies in oncology.

The HHS and the FDA have been ordered by US District Judge John Bates to restore the webpages on diversity following the court’s ruling.

Cidara Therapeutics has reported encouraging top-line outcomes from the Phase IIb NAVIGATE trial of the investigational ...

Bio-Thera Solutions has commenced dosing in the randomised Phase III trial of the antibody-drug conjugate (ADC) BAT8006.